Ascendis Pharma A/S

Ascendis Pharma is a Danish biopharmaceutical company commercializing TransCon technology — long-acting endocrine therapies including the now-approved TransCon PTH for adult hypoparathyroidism. The Russell U.S. Indexes inclusion and the +148% revenue growth reflect the commercial inflection.

Where the run sits:

• Q1 revenue grew 148% YoY to $251M with a 91% gross margin and a 10% operating margin — that growth rate is dramatic, helped by the TransCon PTH commercial launch and the achondroplasia pipeline.
• Trailing P/E is 28x and the FCF yield is 0.3% — fair multiples for a commercial-stage biotech finally inflecting; ROE -56% reflects accounting noise from prior R&D spending.
• Phase 3 data showed TransCon PTH replicated systemic actions of endogenous PTH through Week 182 in adults with hypoparathyroidism — that's long-duration confirmation of a drug that competes against established standard-of-care alternatives.
• Ascendis joined multiple Russell U.S. Indexes (Russell 3000, 1000, 2500, Midcap) — that's a meaningful flow catalyst for what was a Danish-listed foreign issuer with limited U.S. institutional accumulation.

The acceleration runs through the August 6 print. Continued 100%+ revenue growth, operating margin expanding toward 12%, and explicit TransCon PTH and achondroplasia pipeline commentary extends the move; growth slipping toward 60% combined with any pipeline setback invites a 15% pullback at the 90th-percentile chart.